TrialInternational journal of hematology2012

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.

Kensuke Usuki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.